Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for ...

How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein ...

SEATTLE, June 3, 2020 /PRNewswire/ -- AGC Biologic s, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...